Bluebird Bio

bluebird bio is a biotechnology company engaged in researching, developing, and commercializing potentially transformative gene therapies for severe genetic diseases and cancer. The company has built a product platform with a range of therapeutic potential in a variety of indications based on its lentiviral gene addition platform, gene editing and cancer immunotherapy capabilities. The company is developing LentiGlobin gene therapy for sickle cell disease; Lenti-D gene therapy for cerebral adrenoleukodystrophy; and in collaboration with Bristol-Myers Squibb, the company is developing bb2121 (idecabtagene vicleucel) and bb21217 product candidates as treatments for multiple myeloma.
  • TickerBLUE
  • ISINUS09609G1004
  • ExchangeNASDAQ Stock Market
  • SectorPharmaceuticals & Biotechnology
  • CountryUnited States
Wedbush Research

Wedbush Morning Call - Jan 19 2021 6:57AM

Andreas Argyrides ...
  • Ashiq Mubarack
  • David Nierengarten
  • Kenneth Shields
  • Laura Chico
  • Liana Moussatos
  • Matthew Barcus
  • Robert Driscoll
  • Shveta Dighe

The Week Ahead in Life Sciences

David Nierengarten ...
  • Matthew Barcus

2021 Blue Splits Into Two

Wedbush Research

Wedbush Morning Call - Jan 11 2021 6:56AM

Dave Nicoski ...
  • Ross LaDuke

Vermilion Short Shots: Technically Vulnerable Stocks

Short Shots is a collection of technically vulnerable charts culled from the Negative Inflecting and Toppy columns within our Weekly Compass report or from various technical screening processes. The charts contained in this report have developed concerning technical patterns that suggest further price deterioration is likely. For these reasons Short Shots can also be a great source of ideas for investors interested in short-selling candidates.

Dave Nicoski ...
  • John Betz

Vermilion Compass: Weekly Equity Strategy

• Bullish but selective. As we alluded to last week, our long-term bullish outlook remains intact. However, looking through the charts we find a growing list of extended and parabolic patterns. While we continue to remain bullish, we acknowledge the likelihood of backing and filling, or a pause, is building. The further a stock's price action moves from its 200-day, the greater the possibility of a corrective reversion to the mean, or pullback. In last week's Compass our example was Boeing Corporation (BA). The stock is trading 40% above its 200-day moving average, and this rate of momentum...

2 directors sold after exercising options/sold

Two Directors at Bluebird Bio Inc sold after exercising options/sold 1,861 shares at between 127.604USD and 128.605USD. The significance rating of the trade was 54/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly showing Close periods where trading activity ...

Wedbush Research

Wedbush Morning Call - Jan 19 2021 6:57AM

Andreas Argyrides ...
  • Ashiq Mubarack
  • David Nierengarten
  • Kenneth Shields
  • Laura Chico
  • Liana Moussatos
  • Matthew Barcus
  • Robert Driscoll
  • Shveta Dighe

The Week Ahead in Life Sciences

David Nierengarten ...
  • Matthew Barcus

2021 Blue Splits Into Two

Wedbush Research

Wedbush Morning Call - Jan 11 2021 6:56AM

An unfavourable environment weighs on BLUEBIRD BIO, which sees a downgrade to Negative

The independent financial analyst theScreener just requalified the general evaluation of BLUEBIRD BIO (US), active in the Biotechnology industry. As regards its fundamental valuation, the title still shows 1 out of 4 stars and its market behaviour is seen as risky. theScreener believes that the unfavourable environment weighs on the sector and penalises the company, which sees a downgrade to its general evaluation to Negative. As of the analysis date September 8, 2020, the closing price was USD 56.38 and its target price was estimated at USD 42.27.

ResearchPool Subscriptions

Get the most out of your insights

Get in touch